Main Conference Day One Thursday, May 29, 2008
| 7:45 |
Continental Breakfast, Conference Registration And Networking In The Solutions Zone |
|
| 8:30 |
Welcoming Remarks |
|
| 8:40 |
Chair’s Opening Remarks |
|
| 8:50 |
KEYNOTE PANEL: Aligning IP Strategy And The Business – Becoming A Resource Not A Roadblock
Scott Brown, Vice President, General Counsel, Head of NIBR Patents, Novartis Institute of Biomedical Research, Novartis
Guy Donatiello, Vice President Intellectual Property, Endo Pharmaceuticals
Karen F. Clark, Associate General Counsel, Global Health, Well Being and Beauty Care, The Procter & Gamble Company
Dorothy Auth, Partner Litigation and Intellectual Property, Cadwalader Wickersham & Taft |
|
| 9:30 |
Developing Business-Aligned Portfolio Management Strategies
Li Westerlund, Vice President of Global Intellectual Property, Bavarian Nordic |
|
| 10:10 |
Morning Refreshment And Networking Break In The Solutions Zone |
|
| 10:50 |
KEYNOTE PANEL: Patent Reform, Resolutions & Additional Rulings – Interpretations, Impacts And Strategies For The Challenge Ahead
Robert Hrubiec, Vice President Intellectual Property and Chief Patent Counsel, Cephalon
Gary Creason, Vice President Intellectual Property, AVEO Pharmaceuticals
John T. Li Patents, Head, Biology & Biologics, Novartis Institutes for Biomedical Research, Novartis
Robert J. Paradiso, Partner, Head of Life Sciences Patent Practice, Lowenstein Sandler |
|
| 11:30 |
Integrating IP And Regulatory Practices To Create A Comprehensive Strategy To Maximise Patent Lifecycles
Martin Voet, Senior Vice President, Chief Intellectual Property Counsel, Allergan |
|
| 12:10 |
Networking Luncheon For All Conference Attendees |
|
| |
Concurrent Tracks |
| |
TRACK A: STRATEGIC IP PORTFOLIO MANAGEMENT |
TRACK B: INNOVATIVE IP LIFE CYCLE EXTENSION |
| 1:20 |
Chairperson’s Opening Remarks
Sam Baxter, Chief Technology Officer, IP.com |
Chairperson’s Opening Remarks |
|
| 1:30 |
Building A Portfolio With Purpose And Value
Balaram Gupta, Associate Vice President, U.S. Patent Operations, Sanofi Aventis |
Identifying Viable Pharmaceutical Extension Strategies In Today’s Regulatory Environment
Geraldine Baldwin, Director Patents, Schering-Plough |
|
| 2:10 |
Adaptive Portfolio Management Strategies In Light Of Recent Rule Changes
Jim Diehl, Executive Director of Intellectual Property and Associate General Counsel, Rigel Pharmaceuticals |
Leveraging On The Interaction Between FDA Regulatory Law And Patent Law To Extend Market Exclusivity
Luisa Bigornia, Vice President Intellectual Property, BioMarin Pharmaceutical |
|
| 2:50 |
Afternoon Refreshment And Networking Break In The Solutions Zone |
Afternoon Refreshment And Networking Break In The Solutions Zone |
|
| 3:30 |
Portfolio Development From A Licensing Perspective
Mark E. Boulding, Senior Vice President and General Counsel, PTC Therapeutics |
Use Of Patent & Regulatory Exclusivities To Optimize Product Life Cycle
Stephen Donovan, Vice President and Assistant General Counsel, Allergan |
|
| 4:10 |
PANEL: Biosimilars And Follow-On Biologics – Preparing For The Road Ahead
James Kelley, Associate General Counsel, Eli Lilly & Co
John M. Engel, Managing Partner, Engel & Novitt, LLP
Bradford (Jim) Badke, Partner, Ropes & Gray LLP |
|
| 4:50 |
PharmaBiotech IP Summit 2008 Gala Cocktail Party |
|
Main Conference Day Two Friday, May 30, 2008
| 8:00 |
Continental Breakfast And Networking In The Solutions Zone |
|
| 8:40 |
Chair’s Opening Remarks
Dianne Elderkin, Partner, Patent Litigation, Woodcock Washburn |
|
| 8:50 |
Aligning R&D, Portfolio Management, And Life Cycle Management To Enhance Protection
Renee Kosslak, General Patent Counsel, PDL BioPharma |
|
| 9:30 |
KEYNOTE PANEL: Ensuring Protection and Enforcement Post KSR
James Gould, Legal Director – Global Patent Litigation, Schering-Plough
Gerald Murphy, Partner, Intellectual Property & Life Sciences, Birch Stewart Kolasch & Birch
Kathleen Fonda, Legal Advisor, Office Of Patent Legal Administration, USPTO
Cindy Clay, Senior Counsel - Intellectual Property, Global Personal Health Care and Pharmaceuticals, The Procter & Gamble Company |
|
| 10:10 |
Morning Refreshment And Networking Break In The Solutions Zone |
|
| 10:50 |
Effective IP Protection, Enforcement And Commercialisation – An Innovator’s Perspective
Winston Henderson, Vice President, General Counsel, Surface Logix |
|
| 11:30 |
Critically Evaluating Freedom To Operate Issues To Maximise Commercial Opportunities: The “Dark Side” Of The Patent Asset
David Earp, Senior Vice President Business Development and Chief Patent Counsel, Geron Corporation |
|
| 12:10 |
Networking Luncheon For All Conference Attendees |
|
| |
Concurrent Tracks |
| |
TRACK A: PATENT ENFORCEMENT AND PROTECTION |
TRACK B: COMMERCIALISING IP |
| 1:20 |
Chair’s Opening Remarks
Chris Lewis, Shareholder, Ratner Prestia |
Chair’s Opening Remarks
Joshua R. Slavitt, Partner, Intellectual Property Law, Pepper Hamilton |
|
| 1:30 |
Post KSR & Pfizer v. Apotex - Implications For Pharmaceutical and Biotech Patent Validity
James Kelley, Associate General Counsel, Eli Lilly & Co |
PANEL: Providing Quick And Efficient Due Diligence Reviews To Enhance The Commercial Value Of Licensing And Transactions
Tom Plant, Assistant General Patent Counsel, Eli Lilly & Co
Jennifer Tegfeldt, Director Business Initiatives and Strategy, Genzyme Corporation
Ira Weiss, VP of Finance and Operations, BioDtech |
|
| 2:10 |
Leveraging On IP As A Business Asset To Unlock Commercial Value
Lee Caffin, Divisional Vice President Global IP Strategy, Abbott Laboratories |
Intellectual Property Valuation – Putting a Dollar Value on Intangible Assets
Reinhold Nowak, General Director, Dennemeyer
Nils Omland, Director, Dennemeyer AG |
|
| 2:50 |
Afternoon Refreshment And Networking Break In The Solutions Zone |
Afternoon Refreshment And Networking Break In The Solutions Zone |
|
| 3:30 |
Demystifying Apportionment Of Damages
Margaret Snowden, Vice President Intellectual Property, Impax Laboratories |
Valuation of IP In Relation to Corporate Transactions and IP Commercialisation
Joseph Vittiglio, Corporate Attorney, AVEO Pharmaceuticals
Hugh M. Cole, Vice President of Business Development, Shire Human Genetic Therapies |
|
| 4:10 |
CLOSING PANEL SESSION & CHAMPAGNE HAPPY HOUR: Effective Enforcement & Protection of Critical Assets in Today’s Environment |
|
| 4:50 |
Close of PharmaBiotech IP Summit 2008 |
|
|
© 2007 WBR. All rights reserved. 
